MarketCapExport financials
Eli Lilly and Company (LLY)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Eli Lilly and Company LLY
$ 1 143.12
0.02%
Facebook
X
Telegram
Eli Lilly and Company Financial Ratios 2025-2006 | LLY
Brief overview of Eli Lilly and Company's multiples and efficiency
Current figures are compared with the company's own five-year history for 2021–2025.
The valuation comparison uses P/E 45.55x (median 47.54x), EV/EBITDA 142.87x (median 21.3x), P/S 14.43x (median 14.43x). Current valuation broadly matches recent historical reference points; the difference from five-year medians is 0%.
The 1/P/E calculation produces a 2.2% earnings yield. It does not capture future growth or capital structure.
The latest available business-quality ratios are ROE 77.8%, ROA 18.4%, ROCE 21%. Current resource returns are convincing and help explain a higher market valuation.
Price, earnings and growth produce a PEG of 4.99x. A high value reduces the cushion if growth slows.
The cash conversion cycle increased 95.3 days to 290.7 days, weakening working-capital efficiency.
What the ratios show
Eli Lilly and Company's valuation and business quality look relatively balanced, with no pronounced distortion in either direction.
Annual Financial Ratios Eli Lilly and Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
45.6 | 73.7 | 126.9 | 47.5 | 40.4 | 29.5 | 16.4 | 37.2 | -443.7 | 30.0 | 36.3 | 33.5 | 12.7 | 15.2 | 10.1 | 7.1 | 8.8 | -25.1 | - | - |
P/S |
14.4 | 17.3 | 19.5 | 10.4 | 8.0 | 7.4 | 6.1 | 4.9 | 4.0 | 3.9 | 4.4 | 4.1 | 2.6 | 2.7 | 1.8 | 1.6 | 1.7 | 2.6 | - | - |
EPS |
23 | 11.8 | 5.8 | 6.9 | 6.2 | 6.8 | 8.9 | 3.1 | -0.2 | 2.6 | 2.3 | 2.2 | 4.3 | 3.7 | 3.9 | 4.6 | 3.9 | -1.9 | - | - |
EV (Enterprise Value) |
933 B | 777 B | 662 B | 295 B | 222 B | 179 B | 171 B | 146 B | 117 B | 102 B | 105 B | 97.9 B | 73.3 B | 77.7 B | 57.9 B | 30 B | 33.6 B | 46.6 B | -3.22 B | -3.11 B |
EBITDA per Share |
2.23 | 1.96 | 1.7 | 1.69 | 1.71 | 1.46 | 7.33 | 7.59 | 5.69 | 4.88 | 4.54 | 4.24 | 6.26 | 5.65 | 6.9 | 1.2 | 1.18 | 1.03 | - | - |
EV/EBITDA |
467.2 | 439.6 | 433.5 | 193.6 | 142.9 | 25.9 | 21.3 | 16.0 | 16.3 | 16.4 | 18.3 | 17.9 | 8.7 | 9.8 | 5.8 | 22.6 | 25.9 | 41.5 | 3.1 | - |
PEG |
4.99 | -7.63 | -9.49 | -6.97 | -12.42 | -5.66 | 0.09 | 0.02 | 4.12 | 2.13 | 29.34 | -0.69 | 0.72 | -1.76 | -0.68 | - | - | - | - | - |
P/B |
8.4 | 9.9 | 10.4 | 6.0 | 4.6 | 3.9 | 50.6 | 11.0 | 7.8 | 5.8 | 6.0 | 5.2 | 3.4 | 4.2 | 3.2 | 1.2 | 1.4 | 1.8 | - | - |
P/CF |
55.9 | 88.5 | 156.8 | 39.1 | 30.6 | 28.1 | 39.2 | 48.0 | 26.2 | 21.9 | 76.2 | 28.5 | 12.8 | 14.6 | 7.9 | 5.2 | 8.8 | 7.1 | - | - |
ROE % |
77.78 | 74.20 | 48.65 | 58.64 | 62.16 | 109.79 | 308.19 | 29.63 | -1.75 | 19.44 | 16.51 | 15.53 | 26.56 | 27.67 | 32.12 | 40.82 | 45.45 | -30.75 | - | - |
ROA % |
18.35 | 13.45 | 8.19 | 12.62 | 11.44 | 13.28 | 21.17 | 7.36 | -0.45 | 7.05 | 6.77 | 6.43 | 13.29 | 11.89 | 12.92 | 16.35 | 15.76 | -7.09 | - | - |
ROCE % |
- | - | - | - | - | - | 21.04 | 19.32 | 14.51 | 13.92 | 13.14 | 12.82 | 21.07 | 19.28 | 25.55 | - | - | - | - | - |
Current Ratio |
- | - | - | - | - | - | 1.2 | 1.7 | 1.3 | 1.4 | 1.5 | 1.1 | 1.5 | 1.6 | 1.6 | - | - | - | - | - |
DSO |
80.5 | 81.4 | 85.5 | 86.8 | 80.9 | 77.5 | 90.6 | 92.2 | 84.0 | 82.0 | 74.5 | 70.7 | 63.5 | 62.8 | 63.7 | 54.1 | 51.2 | 24.9 | - | - |
DIO |
352.3 | 289.7 | 259.8 | 225.6 | 196.3 | 238.7 | 246.7 | 233.4 | 268.1 | 229.9 | 249.7 | 202.8 | 217.8 | 201.2 | 165.6 | - | - | - | - | - |
DPO |
142.1 | 126.3 | 116.7 | 99.1 | 81.8 | 100.2 | 108.6 | 80.2 | 84.8 | 87.1 | 97.0 | 83.5 | 83.2 | 90.4 | 81.0 | - | - | - | - | - |
Operating Cycle |
432.8 | 371.1 | 345.3 | 312.4 | 277.2 | 316.2 | 337.3 | 325.6 | 352.1 | 311.9 | 324.1 | 273.5 | 281.3 | 264.0 | 229.3 | 54.1 | 51.2 | 24.9 | - | - |
Cash Conversion Cycle |
290.7 | 244.8 | 228.6 | 213.2 | 195.4 | 215.9 | 228.7 | 245.5 | 267.2 | 224.8 | 227.2 | 190.0 | 198.1 | 173.5 | 148.3 | 54.1 | 51.2 | 24.9 | - | - |
All numbers in USD currency
Quarterly Financial Ratios Eli Lilly and Company
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 | 2010-Q1 | 2009-Q3 | 2009-Q2 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
7.95 | 8.27 | 6.22 | 6.3 | 3.07 | 1.08 | 3.29 | 2.49 | -0.06 | 1.96 | 1.49 | - | 1.61 | 1.06 | 2.11 | - | 1.22 | 1.53 | 1.49 | - | 1.33 | 1.56 | 1.6 | 1.64 | 1.37 | 1.44 | 4.33 | 1.11 | 1.13 | -0.25 | 1.16 | -1.58 | 0.53 | 0.96 | -0.1 | 0.73 | 0.74 | 0.71 | 0.42 | 0.45 | 0.75 | 0.57 | 0.5 | 0.4 | 0.47 | 0.68 | 0.68 | 0.68 | 1.11 | 1.12 | 1.42 | 0.75 | 1.18 | 0.83 | 0.91 | - | 1.11 | 1.07 | 0.95 | - | - | - | - | - |
EBITDA per Share |
1.17 | 0.57 | 1.57 | - | 0.51 | - | - | 0.44 | - | - | 0.4 | - | 1.27 | - | 0.48 | - | 1.22 | - | 0.39 | - | 1.05 | 0.66 | 0.3 | - | 0.98 | 0.66 | 0.36 | - | 1.24 | 0.82 | 0.4 | - | 1.1 | 0.74 | 0.37 | - | 1.09 | 0.72 | 0.36 | - | 1.02 | 0.68 | 0.34 | - | 0.97 | 0.65 | 0.33 | - | 1.01 | 0.69 | 0.35 | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
99.09 | 95.65 | 78.76 | 77.17 | 63.70 | 45.69 | 54.81 | 44.95 | 41.86 | 62.76 | 61.14 | 49.12 | 70.69 | 56.28 | 75.92 | 55.53 | 76.95 | 87.67 | 91.91 | 72.26 | 129.64 | 156.32 | 182.20 | 319.09 | 273.16 | 236.76 | 183.20 | 32.88 | 7.14 | 0.24 | 11.58 | -1.76 | 18.04 | 18.80 | 15.45 | 19.54 | 17.32 | 17.25 | 16.04 | 16.53 | 16.03 | 13.80 | 14.45 | 15.55 | 16.89 | 20.46 | 22.53 | 26.57 | 28.05 | 30.20 | 29.61 | 27.68 | 31.21 | 31.07 | 32.62 | 25.78 | 36.28 | 40.33 | 43.41 | 45.12 | 48.15 | 11.93 | 9.51 | 13.53 |
ROA % |
21.80 | 19.90 | 14.84 | 14.11 | 12.01 | 8.82 | 10.75 | 9.15 | 8.71 | 12.86 | 11.95 | 9.42 | 12.33 | 9.27 | 12.16 | 8.11 | 10.70 | 11.42 | 11.64 | 8.74 | 12.55 | 13.15 | 13.50 | 21.17 | 19.93 | 19.36 | 15.39 | 7.36 | 1.12 | -0.27 | 2.57 | -0.45 | 5.22 | 5.99 | 5.67 | 7.05 | 6.41 | 6.65 | 6.42 | 6.77 | 6.61 | 5.71 | 5.99 | 6.46 | 7.34 | 9.41 | 10.86 | 13.29 | 13.63 | 14.07 | 13.34 | 11.89 | 13.15 | 12.85 | 13.31 | 10.37 | 14.72 | 15.92 | 16.95 | 17.28 | 17.23 | 4.59 | 3.47 | 4.30 |
DSO |
76.5 | 79.6 | 78.5 | 76.9 | 80.0 | 85.0 | 76.3 | 83.5 | 75.3 | 82.6 | 94.5 | - | 44.1 | 44.5 | 75.9 | - | 79.1 | 77.3 | 76.9 | - | 93.4 | 97.5 | 81.2 | 67.9 | 75.8 | 73.6 | 81.9 | 74.4 | 79.0 | 75.1 | 78.8 | 71.9 | 83.6 | 81.5 | 86.7 | 63.8 | 70.8 | 68.0 | 70.7 | 59.6 | 64.6 | 64.4 | 66.3 | 57.6 | 60.5 | 59.8 | 65.0 | 54.0 | 54.3 | 52.9 | 55.1 | 51.1 | 55.9 | 54.4 | 56.5 | - | 53.4 | 52.5 | 54.2 | 51.6 | 49.7 | 51.7 | 48.0 | - |
DIO |
437.3 | 340.7 | 351.8 | 378.8 | 344.0 | 293.0 | 264.5 | 300.0 | 237.9 | 235.9 | 248.3 | - | 110.7 | 124.2 | 171.3 | - | 246.6 | 174.9 | 185.6 | - | 273.8 | 297.2 | 269.3 | 227.0 | 247.8 | 258.8 | 252.0 | 250.2 | 245.2 | 229.0 | 254.4 | 302.1 | 349.6 | 356.8 | 382.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
155.5 | 118.5 | 126.5 | 140.1 | 129.8 | 122.1 | 113.5 | 133.8 | 120.4 | 113.3 | 110.7 | - | 48.6 | 45.7 | 68.3 | - | 100.9 | 75.6 | 78.8 | - | 110.5 | 120.0 | 113.1 | 100.0 | 109.1 | 114.0 | 104.7 | 97.5 | 95.5 | 89.2 | 94.6 | 100.7 | 110.6 | 112.9 | 131.5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | 455.7 | 424.1 | 378.1 | 340.9 | 383.5 | 313.3 | 318.4 | 342.9 | - | 154.8 | 168.6 | 247.2 | - | 325.7 | 252.2 | 262.5 | - | 367.2 | 394.7 | 350.4 | 294.9 | 323.6 | 332.4 | 333.9 | 324.6 | 324.2 | 304.1 | 333.2 | 374.0 | 433.3 | 438.3 | 468.7 | 63.8 | 70.8 | 68.0 | 70.7 | 59.6 | 64.6 | 64.4 | 66.3 | 57.6 | 60.5 | 59.8 | 65.0 | 54.0 | 54.3 | 52.9 | 55.1 | 51.1 | 55.9 | 54.4 | 56.5 | - | 53.4 | 52.5 | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | 315.6 | 294.2 | 255.9 | 227.4 | 249.7 | 192.8 | 205.1 | 232.2 | - | 106.2 | 122.9 | 178.9 | - | 224.8 | 176.6 | 183.6 | - | 256.7 | 274.7 | 237.3 | 194.9 | 214.4 | 218.4 | 229.2 | 227.1 | 228.7 | 214.9 | 238.6 | 273.3 | 322.6 | 325.4 | 337.2 | 63.8 | 70.8 | 68.0 | 70.7 | 59.6 | 64.6 | 64.4 | 66.3 | 57.6 | 60.5 | 59.8 | 65.0 | 54.0 | 54.3 | 52.9 | 55.1 | 51.1 | 55.9 | 54.4 | 56.5 | - | 53.4 | 52.5 | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Eli Lilly and Company, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Biotechnology industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
InflaRx N.V.
IFRX
|
$ 1.68 | 0.58 % | $ 113 M |  Germany |
 |
Immutep Limited
IMMP
|
$ 4.27 | 0.46 % | $ 6.22 B |  Australia |
 |
Immunome
IMNM
|
$ 21.17 | 1.29 % | $ 1.85 B |  USA |
 |
Immuron Limited
IMRN
|
$ 1.07 | 0.46 % | $ 247 M | Australia |
 |
Immatics N.V.
IMTX
|
$ 7.73 | 1.84 % | $ 946 M | Germany |
 |
Immunic
IMUX
|
$ 8.07 | 1.38 % | $ 1.26 B | USA |
 |
Immunovant
IMVT
|
$ 33.25 | 0.18 % | $ 6.07 B | USA |
 |
Innate Pharma S.A.
IPHA
|
$ 1.58 | 1.28 % | $ 142 M |  France |
 |
Incyte Corporation
INCY
|
$ 114.13 | 0.06 % | $ 22.3 B | USA |
 |
InMed Pharmaceuticals
INM
|
$ 1.33 | 0.01 % | $ 5.54 M |  Canada |
 |
INmune Bio
INMB
|
$ 1.94 | 0.52 % | $ 48 M | USA |
 |
Inovio Pharmaceuticals
INO
|
$ 1.15 | 2.05 % | $ 53.9 M | USA |
 |
Insmed Incorporated
INSM
|
$ 103.83 | 2.33 % | $ 20.7 B | USA |
 |
Innoviva
INVA
|
$ 20.64 | 0.68 % | $ 1.39 B | USA |
 |
Iovance Biotherapeutics
IOVA
|
$ 14.15 | 0.63 % | $ 5.06 M | USA |
 |
Ironwood Pharmaceuticals
IRWD
|
$ 3.65 | 0.27 % | $ 591 M | USA |
 |
Inventiva S.A.
IVA
|
$ 3.48 | 2.89 % | $ 208 M | France |
 |
Jaguar Health
JAGX
|
$ 4.73 | 29.23 % | $ 11 M | USA |
 |
Jazz Pharmaceuticals plc
JAZZ
|
$ 236.04 | 0.16 % | $ 14.4 B |  Irlanda |
 |
Johnson & Johnson
JNJ
|
$ 252.93 | 0.03 % | $ 609 B | USA |
 |
Kala Pharmaceuticals
KALA
|
$ 0.36 | 0.86 % | $ 2.93 M | USA |
 |
Kiniksa Pharmaceuticals, Ltd.
KNSA
|
$ 76.31 | 0.69 % | $ 5.66 B | USA |
 |
Kodiak Sciences
KOD
|
$ 93.81 | 0.32 % | $ 4.99 B | USA |
 |
Karyopharm Therapeutics
KPTI
|
$ 0.67 | 1.51 % | $ 7.33 K | USA |
 |
Keros Therapeutics
KROS
|
$ 11.52 | 1.41 % | $ 429 M | USA |
 |
Krystal Biotech
KRYS
|
$ 334.85 | 3.9 % | $ 9.69 B | USA |
 |
Kura Oncology
KURA
|
$ 10.62 | 0.09 % | $ 931 M | USA |
 |
Kymera Therapeutics
KYMR
|
$ 109.85 | 2.29 % | $ 9.28 B | USA |
 |
Kazia Therapeutics Limited
KZIA
|
$ 9.35 | 0.86 % | $ 143 M | Australia |
 |
Lineage Cell Therapeutics
LCTX
|
$ 0.93 | 2.73 % | $ 214 M | USA |
 |
Legend Biotech Corporation
LEGN
|
$ 18.77 | 1.1 % | $ 6.92 B | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
$ 306.77 | 1.26 % | $ 5.93 B | USA |
 |
Longeveron
LGVN
|
$ 2.51 | 0.39 % | $ 44.1 B | USA |
 |
Lipocine
LPCN
|
$ 2.07 | 0.98 % | $ 11.3 M | USA |
 |
Liquidia Corporation
LQDA
|
$ 27.64 | 2.32 % | $ 2.38 B | USA |
|
Larimar Therapeutics
LRMR
|
$ 2.86 | 1.75 % | $ 238 M | USA |
 |
Lantern Pharma
LTRN
|
$ 0.94 | 9.3 % | $ 10.2 M | USA |
 |
Lexicon Pharmaceuticals
LXRX
|
$ 1.74 | 0.82 % | $ 632 M | USA |
 |
Mustang Bio
MBIO
|
$ 0.46 | 1.16 % | $ 2.26 M | USA |
 |
Moleculin Biotech
MBRX
|
$ 0.48 | 0.42 % | $ 569 K | USA |
 |
Seres Therapeutics
MCRB
|
$ 2.85 | 0.34 % | $ 25.2 M | USA |
 |
Madrigal Pharmaceuticals
MDGL
|
$ 493.62 | 0.1 % | $ 11.1 B | USA |
 |
MediWound Ltd.
MDWD
|
$ 13.51 | 0.22 % | $ 368 M |  Israel |
 |
Mesoblast Limited
MESO
|
$ 14.22 | 0.99 % | $ 17.2 B | Australia |
 |
MacroGenics
MGNX
|
$ 3.77 | 5.31 % | $ 238 M | USA |
 |
MeiraGTx Holdings plc
MGTX
|
$ 10.92 | 1.2 % | $ 878 M | USA |
 |
Mirum Pharmaceuticals
MIRM
|
$ 81.43 | 0.07 % | $ 4.09 B | USA |
 |
Milestone Pharmaceuticals
MIST
|
$ 0.78 | 0.25 % | $ 82.9 M | Canada |
 |
MannKind Corporation
MNKD
|
$ 3.82 | 0.53 % | $ 1.17 B | USA |